Alnylam Achieves 13.74% ROIC Over 5.66% WACC, 2.43x Efficiency
Alnylam Pharmaceuticals reported ROIC of 13.74% against WACC of 5.66%, yielding a 2.43 ROIC/WACC ratio that outpaces peers. BioMarin’s ratio stands at 1.19 while Ionis, Sarepta and Agios show negative ratios of -2.37, -5.41 and -4.93 respectively.
1. Capital Efficiency Highlights
Alnylam Pharmaceuticals’ ROIC of 13.74% versus a WACC of 5.66% produces a ROIC/WACC ratio of 2.43, demonstrating its ability to generate returns well above its cost of capital. This efficiency signals strong project selection and cost management within its RNAi therapeutics pipeline.
2. Industry Peer Comparison
Among peers, BioMarin records a ratio of 1.19, while Ionis, Sarepta and Agios report negative ratios of -2.37, -5.41 and -4.93 respectively. Alnylam’s superior ratio underscores its competitive advantage in capital deployment and potential to attract investment over less efficient industry peers.